Orchid’s 11-slide deck is a focused clinical argument for a new standard of care in IVF. Rather than leading with market size or revenue growth, the presentation emphasizes the technical superiority of its whole-genome embryo reports compared to traditional PGT-A testing. The deck highlights specific screening capabilities, such as a Neurodevelopmental Disorders panel covering 230+ genes and a Hereditary Cancer panel covering 90+ genes. By leaning heavily on social proof from world-renowned embryologists and a stark competitive matrix, Orchid positions itself as the only provider capable of d…
Key takeaways
- The deck uses a minimalist aesthetic to keep the focus on high-stakes medical outcomes, specifically the mission to 'Have healthy babies' (Slide 1).
- Orchid defines its operational workflow clearly, explaining how 4-8 cells are sent from IVF clinics to their lab for analysis (Slide 2).
- The startup differentiates itself by screening for complex de novo variants in 230+ genes related to intellectual disability and autism (Slide 3).
- Clinical depth is demonstrated through a dedicated Hereditary Cancer Panel that screens for over 90 genes associated with both pediatric and adult-onset cancers (Slide 4).
- Expert validation is a core pillar of the deck, featuring testimonials from Stanford faculty and IVF pioneers on the Scientific Advisory Board (Slide 5).
- A detailed competitive matrix claims Orchid can detect five categories of conditions that 'Alternatives' cannot, including birth defects across 900+ genes (Slide 6).
- The deck omits traditional venture slides such as team bios, market sizing (TAM/SAM/SOM), financial projections, and the specific investment ask.
- As reported by Business Insider, this 11-slide presentation was instrumental in raising a $12M Series A in 2024.
The Clinical Case for Whole-Genome Embryo Screening
Orchid’s pitch deck is a notable departure from the hyper-visual, metric-heavy decks common in SaaS. Operating in the highly regulated and sensitive field of reproductive genetics, Orchid uses its 11 slides to establish a singular narrative: that traditional embryo testing is insufficient, and Orchid is the only viable solution for comprehensive risk mitigation. As reported by Business Insider, this deck supported a $12M Series A round in 2024, a testament to the power of clinical specificity over general market hype.
Slide 1-2: The Mission and the Mechanism
The deck opens with a stark, minimalist title slide featuring the tagline: "Have healthy babies." This is a high-gravity emotional hook that immediately defines the stakes of the business. It moves quickly from the 'why' to the 'how' on Slide 2. This slide illustrates the IVF process where multiple embryos are created, and Orchid’s role is to "identify the embryo with the fewest genetic risks."
Crucially, Slide 2 outlines the logistics of the service. It specifies that an embryologist at an IVF clinic sends "4-8 cells from each embryo" to Orchid’s lab. This detail is vital for investors because it demonstrates that Orchid does not need to build its own clinics; it functions as a specialized diagnostic layer that plugs into the existing multi-billion dollar IVF infrastructure.
Slide 3-4: Deep Diving into Disease Panels
Slides 3 and 4 serve as the technical core of the deck. Rather than making broad claims about 'better health,' Orchid lists specific clinical panels. Slide 3 introduces the Neurodevelopmental Disorders (NDD) Panel , which screens 230+ genes and copy number variants. It specifically targets variants that cause intellectual disability and autism, noting that these are typically de novo variants —mutations that appear for the first time in a family member.
Slide 4 focuses on the Hereditary Cancer Panel . It claims to screen 90+ genes associated with both pediatric and adult cancers. The slide lists specific conditions like Li-Fraumeni syndrome and retinoblastoma, as well as adult-onset risks for breast, ovarian, and prostate cancer. By listing these specific, well-known medical conditions, Orchid moves the conversation from 'genetic screening' to 'preventative oncology,' which carries significantly higher perceived value for both parents and clinicians.
Slide 5: The Power of Expert Endorsement
In biotech, the 'who' is often as important as the 'what.' Slide 5, titled "Backed by top embryologists and embryo testing experts," features two heavyweights in the field. Barry Behr, PhD, HCLD , a Professor Emeritus at Stanford Medical Center, and Jacques Cohen, PhD, HCLD , described as a "pioneering embryologist and foundational figure in IVF," both provide testimonials.
Dr. Behr’s quote frames Orchid as the solution to "one of the 21st century’s greatest health challenges," while Dr. Cohen describes the whole genome report as a "significant leap forward." For a Series A investor, these endorsements act as a proxy for technical due diligence. If the pioneers of IVF believe this is the future, the execution risk is perceived as lower.
Slide 6: The Competitive Moat
Slide 6 is the 'money slide' of the deck. It features a competitive matrix titled "Maximize your chance at a successful pregnancy and healthy child with Orchid." It compares Orchid against "Alternatives" (presumably standard PGT-A testing).
The matrix is divided into two sections. The first, "Superior results for traditional tests," shows Orchid matching or beating alternatives on Aneuploidy and Triploidy. The second section, "Identify conditions previously impossible to detect," is where Orchid claims total dominance. It lists five categories where alternatives have an 'X' and Orchid has a checkmark:
Microduplications and deletions (50+ syndromes) · Neurodevelopmental disorders (200+ genes) · Pediatric and adult onset cancers (90+ genes) · Birth defects (900+ genes) · Predisposition screening (evaluates over 1M+ SNPs)
This slide effectively argues that Orchid isn't just a marginal improvement; it is a categorical shift in what is possible in reproductive medicine.
What Orchid’s Deck Does Well
The strength of this deck lies in its clinical authority . By focusing on specific gene counts (230+, 90+, 900+) and specific disease names, Orchid avoids the 'black box' problem that plagues many biotech startups. They are transparent about what they are looking for and how they find it. This transparency builds trust with sophisticated investors who are wary of over-promised 'AI-driven' health claims.
The visual simplicity is also a strategic choice. The use of ample white space and clean typography suggests a premium, medical-grade service. It feels like a report a doctor would hand a patient, which reinforces the brand's positioning as a clinical partner rather than a disruptive tech play.
What is Missing from the Orchid Deck
Despite raising $12M, the 11 slides provided are missing several components typically found in a Series A deck:
Market Sizing: There is no mention of the Total Addressable Market (TAM). While the IVF market is known to be large and growing, investors usually want to see the company's specific calculation of their slice of that market. · Business Model/Unit Economics: The deck does not disclose the price of a 'Whole Genome Embryo Report' or the margins associated with running these tests. · Regulatory Path: There is no mention of FDA status or CLIA/CAP lab certifications, which are usually critical hurdles in diagnostic fundraising. · The Team: While the advisors are prominent, the actual day-to-day leadership team (CEO, CTO, COO) is not featured in the provided slides. · The Ask: The deck does not state how much they are raising or what the milestones for the next 18-24 months will be.
It is highly likely that these missing elements were covered in a separate 'Data Room' or a longer version of the deck, but their absence in the core narrative suggests that Orchid led with the science and the problem first.
Founder Lessons: Copy the Credibility
Founders in deep-tech or healthcare should take note of Orchid’s social proof strategy . If you are building something that sounds like science fiction—such as screening embryos for autism—you must have the industry’s most respected voices vouching for you early and often. Orchid didn't just put logos of universities; they put the faces and direct quotes of the people who defined the industry.
Additionally, the "Impossible to Detect" framing on Slide 6 is a powerful way to define a competitive advantage. Instead of saying you are 'faster' or 'cheaper,' show that you are doing something that was previously considered a technical impossibility. That is the hallmark of a venture-scale breakthrough.
Final Summary
Orchid’s Series A deck is a masterclass in narrow-focus persuasion . By ignoring the 'fluff' of typical pitch decks and focusing entirely on clinical superiority and expert validation, they successfully navigated a complex, ethically sensitive market to secure $12M in funding. For founders, the lesson is clear: when the science is the product, let the science do the talking.
Frequently asked questions
- Why does the deck omit a team slide?
- While the provided slides do not include a standard team slide with bios, Orchid compensates for this by featuring high-profile members of their Scientific Advisory Board on Slide 5. In biotech, the credibility of the scientific advisors often carries as much weight as the executive team, signaling to investors that the technology is backed by industry-leading experts.
- How does Orchid handle the ethical complexity of its product?
- The deck avoids philosophical debate and instead focuses on clinical utility. By framing the product as a tool to 'identify the embryo with the fewest genetic risks' (Slide 2) and providing panels for severe conditions like cancer and neurodevelopmental disorders, Orchid positions its technology as a logical extension of existing prenatal healthcare.
- What is the primary competitive advantage claimed in the deck?
- Orchid’s primary advantage is the breadth and resolution of its sequencing. Slide 6 explicitly states that while alternatives only handle Aneuploidy, Orchid screens for Triploidy, 200+ NDD genes, 90+ cancer genes, and evaluates over 1 million SNPs for predisposition screening—capabilities labeled as 'previously impossible to detect.'
- Is the lack of financial data a red flag for a Series A?
- In early-stage biotech, clinical milestones and technical defensibility often precede revenue metrics. Orchid’s $12M raise suggests that investors were satisfied with the 'moat' created by their proprietary testing panels and the endorsement of the IVF community, rather than immediate EBITDA projections.
- What is the 'Orchid Workflow' described in the slides?
- The workflow is a B2B2C model. As shown on Slide 2, an embryologist at an existing IVF clinic biopsies the embryo and sends the cells to Orchid’s lab. Orchid then processes the samples and returns a report to the clinic and parents, integrating directly into the existing IVF clinical path.
